Michael D Robbins Selected Research

elotuzumab

10/2019	Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma.
1/2018	Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab.
5/2017	PD-1 blockade enhances elotuzumab efficacy in mouse tumor models.
1/2017	The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and -independent mechanisms.
1/2016	Development and Validation of Electrochemiluminescence Assays to Measure Free and Total sSLAMF7 in Human Serum in the Absence and Presence of Elotuzumab.
1/2015	Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael D Robbins Research Topics

Disease

7	Multiple Myeloma 01/2020 - 01/2015
3	Neoplasms (Cancer) 01/2018 - 01/2017
1	Disease Progression 01/2021
1	Residual Neoplasm 08/2017
1	Obesity 09/2008
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 09/2008
1	Dyslipidemias (Dyslipidemia) 09/2008

Drug/Important Bio-Agent (IBA)

6	elotuzumabIBA 10/2019 - 01/2015
4	Monoclonal AntibodiesIBA 10/2019 - 01/2016
2	Lenalidomide (CC 5013)FDA Link 01/2020 - 01/2015
2	Immunoglobulin G (IgG)IBA 10/2019 - 01/2016
1	Biomarkers (Surrogate Marker)IBA 01/2021
1	Bortezomib (Velcade)FDA Link 01/2020
1	Dexamethasone (Maxidex)FDA LinkGeneric 01/2020
1	ulocuplumabIBA 01/2020
1	CytokinesIBA 05/2017
1	Immunoglobulins (Immunoglobulin)IBA 05/2017
1	ChemokinesIBA 05/2017
1	Membrane Glycoproteins (Membrane Glycoprotein)IBA 01/2017
1	Fatty Acids (Saturated Fatty Acids)IBA 09/2008
1	CholesterolIBA 09/2008

Therapy/Procedure

1	Therapeutics 08/2017